Analysts expect that QIAGEN (NYSE:QGEN) will announce $555.33 million in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for QIAGEN's earnings, with estimates ranging from $554.68 million to $556.50 million. QIAGEN posted sales of $372.10 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 49.2%. The business is scheduled to issue its next quarterly earnings results on Wednesday, May 5th.
According to Zacks, analysts expect that QIAGEN will report full year sales of $2.25 billion for the current fiscal year, with estimates ranging from $2.22 billion to $2.27 billion. For the next financial year, analysts forecast that the company will post sales of $2.29 billion, with estimates ranging from $2.23 billion to $2.38 billion. Zacks Investment Research's sales averages are a mean average based on a survey of research analysts that cover QIAGEN.
QIAGEN (NYSE:QGEN) last issued its quarterly earnings results on Tuesday, February 9th. The company reported $0.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.66 by $0.02. The business had revenue of $571.23 million for the quarter, compared to the consensus estimate of $551.85 million. QIAGEN had a return on equity of 17.51% and a net margin of 11.18%.
QGEN has been the topic of a number of research analyst reports. Norddeutsche Landesbank reissued a "hold" rating on shares of QIAGEN in a report on Wednesday, January 6th. DZ Bank reissued a "neutral" rating on shares of QIAGEN in a report on Wednesday, April 7th. Berenberg Bank reissued a "buy" rating on shares of QIAGEN in a report on Friday, February 19th. Kepler Capital Markets reissued a "buy" rating on shares of QIAGEN in a report on Friday, April 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of QIAGEN in a report on Wednesday, February 17th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. The stock presently has an average rating of "Buy" and a consensus price target of $59.92.
A number of large investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its position in shares of QIAGEN by 214.5% in the fourth quarter. Wells Fargo & Company MN now owns 428,262 shares of the company's stock worth $22,633,000 after acquiring an additional 292,071 shares during the period. Illinois Municipal Retirement Fund raised its position in shares of QIAGEN by 90.6% during the 4th quarter. Illinois Municipal Retirement Fund now owns 14,357 shares of the company's stock worth $759,000 after purchasing an additional 6,823 shares during the last quarter. BlackRock Inc. raised its position in shares of QIAGEN by 2.5% during the 4th quarter. BlackRock Inc. now owns 4,697,341 shares of the company's stock worth $248,255,000 after purchasing an additional 113,391 shares during the last quarter. Morgan Stanley raised its position in shares of QIAGEN by 29.9% during the 4th quarter. Morgan Stanley now owns 937,953 shares of the company's stock worth $49,572,000 after purchasing an additional 216,000 shares during the last quarter. Finally, Schroder Investment Management Group raised its position in shares of QIAGEN by 0.8% during the 4th quarter. Schroder Investment Management Group now owns 170,074 shares of the company's stock worth $7,220,000 after purchasing an additional 1,420 shares during the last quarter. 43.64% of the stock is currently owned by institutional investors.
Shares of QGEN opened at $52.69 on Friday. The firm has a market capitalization of $12.01 billion, a PE ratio of 65.05, a price-to-earnings-growth ratio of 1.29 and a beta of 0.41. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.46 and a quick ratio of 1.22. QIAGEN has a 1-year low of $39.93 and a 1-year high of $59.00. The company's fifty day moving average price is $49.37 and its 200-day moving average price is $51.14.
QIAGEN Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Story: Trading Ex-Dividend
Get a free copy of the Zacks research report on QIAGEN (QGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Differences Between Momentum Investing and Long Term Investing 7 Great Dividend Stocks to Buy For a Comfortable Retirement
There are people who will say the day of set it and forget it retirement accounts are over. But it’s a narrative we’ve heard before. The truth is the formula for saving for and enjoying a comfortable retirement, like the formula for weight loss, hasn’t really changed. A lot depends on whether an individual has the discipline to see it through.
Dividend stocks remain one of the core elements of a retirement portfolio. As individuals near retirement the ability to reinvest dividends allows for a greater total return. And once individuals need to live off their portfolio, the dividends provide a source of income without having to tap their principal.
However, not all dividend stocks are the same and many investors get sucked in by the allure of a high-yield dividend stock. But what you’re really looking for are companies with a history of increasing its dividend. The ability to increase a dividend over time illustrates that the company has a business model that can hold up regardless of how the broader economy is performing.
In this special presentation, we’ll highlight seven stocks that individuals can buy today to capture a stable, recurring dividend.
View the "7 Great Dividend Stocks to Buy For a Comfortable Retirement"